Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
118 hedge funds and large institutions have $612M invested in Accelerate Diagnostics in 2018 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 40 increasing their positions, 26 reducing their positions, and 9 closing their positions.
80% more call options, than puts
Call options by funds: $27.3M | Put options by funds: $15.1M
54% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 26
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
11% more capital invested
Capital invested by funds: $551M → $612M (+$60.8M)
2% more funds holding
Funds holding: 116 → 118 (+2)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stifel Financial
St. Louis,
Missouri
|
+$9.88M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$7.08M |
| 3 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
+$6.02M |
| 4 |
GAM
Griffin Asset Management
New York
|
+$5.59M |
| 5 |
William Blair & Company
Chicago,
Illinois
|
+$5.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$1.92M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$1.38M |
| 3 |
Morgan Stanley
New York
|
-$894K |
| 4 |
Daiwa Securities Group
Tokyo,
Japan
|
-$774K |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$750K |
AXDX Hedge Fund Activity: Q3 2018 in Review
118 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q3 2018, worth a combined $612M — up 11% from $551M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new AXDX positions and 9 closed out — a net gain of 2 holders — while 40 added to existing stakes and 26 trimmed.
The largest buyer was Stifel Financial, opening a new position worth an estimated $9.88M. The largest seller was Oracle Investment Management, cutting an estimated $1.92M.
- 118 institutional investors held Accelerate Diagnostics (AXDX) as of Q3 2018, up from 116 in Q2 2018.
- Funds reported $612M of Accelerate Diagnostics stock for Q3 2018, up 11% quarter-over-quarter.
- 11 funds opened new Accelerate Diagnostics positions in Q3 2018 and 9 closed out, a net change of +2 holders.
- The largest Accelerate Diagnostics buyer in Q3 2018 was Stifel Financial, an estimated $9.88M added.
- The largest Accelerate Diagnostics seller in Q3 2018 was Oracle Investment Management, an estimated $1.92M sold.
Based on aggregated 13F filings for Q3 2018.